Cytokinetics Inc at Needham Healthcare Conference Transcript
Thank you, everyone, for attending the Needham Healthcare Conference.
It's my pleasure to introduce Robert Blum, President and CEO of Cytokinetics.
Thank you to Needham for inviting Cytokinetics to provide this update. Thanks to you here in the room and those who may be listening in on the webcast. I'll be providing a corporate update for Cytokinetics over these next 25 or so minutes; and, in particular, talking about our pipeline of investigational medicines directed to diseases and conditions of severe muscle dysfunction and muscle weakness.
And we start our presentation with pictures of some of those patients who inspire us, who we know quite well, and personally who tour our labs and who provide feedback and guidance as to what will matter most to treating patients with these most severe, devastating diseases.
I'll be making some forward-looking statements. And I will refer you to our recent SEC filings, including our recent 10-K with regard to caveats to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |